More Mayne Pharma Group Ltd. news
Mayne Pharma Group Ltd.ASX: MYX

2017 Half Year Media Release

Feb 23, 2017 at 9:33 PM EST · Issued by Mayne Pharma Group Ltd.

Filed with ASX · Feb 23, 2017 at 9:33 PM EST · 4 pages · English

On 6ix: 6ix.com/news/2017-half-year-media-release

Watch Mayne Pharma's latest callMayne Pharma Group (ASX:MYX) Q4 2026 Earnings Call · Replay · Aug 26↗

Mayne Pharma Group Ltd. on 6ix

In the deck

  • Mayne Pharma Group — H1 FY2017 Earnings Presentation23 slidesFeb 24, 2017

Story so far

  • Media SpeculationFeb 11, 2016
  • 2013 Half Year Media ReleaseFeb 11, 2016
  • Half Year Results and AccountsFeb 11, 2016

Earlier from Mayne Pharma

  • Mayne Pharma launches Butalbital / APAP tablets in the USFeb 15, 2017
  • Mayne Pharma launches Amiodarone 100mg tabletsJan 12, 2017
  • Mayne Pharma launches Fabior and Sorilux in the USJan 10, 2017
  • Update on Status of DOJ InvestigationDec 15, 2016
  • S&P DJ Indices Announces March Quarterly RebalanceNov 7, 2016

Later from Mayne Pharma

  • License and supply agreement for generic Nuvaring in the USFeb 27, 2017
  • Mayne Pharma acquires rights to generic Duragesic in the USMar 8, 2017
  • Clarification statementMay 2, 2017
  • FDA approval and first generic launch of Acticlate tabletsJun 14, 2017
  • Mayne Pharma adds two products to its Australian portfolioSep 14, 2017
All Mayne Pharma news releases↗

Follow Mayne Pharma into a list and get an email when it puts out news.

Follow Mayne Pharma
  • About 6ix
  • Editorial & Sourcing
  • Corrections
  • Contact
  • Privacy
  • Terms
  • Disclaimer